1. Homepage
  2. Equities
  3. Switzerland
  4. SIX SWISS EXCHANGE - BLUE CHIPS SEGMENT
  5. Vifor Pharma AG
  6. News
  7. Press Releases
    VIFN   CH0364749348

VIFOR PHARMA AG

(VIFN)
End-of-day quote SIX SWISS EXCHANGE - BLUE CHIPS SEGMENT  - 
0.000000 CHF    0.00%
05/12Update on the timeline for Vifor Pharma tender offer
BU
05/11Australia shares slide as U.S. inflation data fuels slowdown woes
RE
04/29VIFOR PHARMA AG : Ex-dividend day for final dividend
FA
SummaryNewsRatingsCalendarCompany 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société VIFOR PHARMA AG
05/12Update on the timeline for Vifor Pharma tender offer
BU
04/28Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruri..
AQ
04/2694th Vifor Pharma Group Annual General Meeting
BU
04/04DIAMOND TRIAL : Veltassa® enables patients to achieve long-term potassium control and opti..
BU
03/28Publication of definitive end result for Vifor Pharma tender offer
BU
03/23CSL BEHRING AG - PUBLICATION OF PROV : Participation rate of 94 percent
AQ
03/23PUBLICATION OF PROVISIONAL END RESUL : Participation rate of 94 percent
BU
03/03Vifor Pharma Group - Publication of provisional interim result for Vifor Pharma tender ..
AQ
03/03PUBLICATION OF PROVISIONAL INTERIM R : Participation rate of 74 percent
BU
03/02Cordenpharma completes acquisition of 3 facilities from vifor pharma
AQ
02/28Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe prurit..
BU
02/17VIFOR PHARMA : Investor factsheet
PU
02/17VIFOR PHARMA : Annual Report 2021 – Full Version
PU
02/17Vifor Pharma reports sustained growth in 2021
BU
02/04RAYALDEE Launched in Germany by OPKO Health's Licensee, VFMCRP
AQ
02/02Vifor Pharma appoints two new members to the Executive Committee
BU
01/20ChemoCentryx Announces EU Approval of TAVNEOS (avacopan) for the Treatment of ANCA-Asso..
AQ
01/19VFMCRP receives EU approval for Tavneos® for the treatment of ANCA-associated vasculiti..
BU
01/18VIFOR PHARMA : Fairness Opinion Vifor Pharma
PU
01/18CSL Behring AG publishes Offer Prospectus on public tender offer for all publicly held ..
BU
2021Vifor Pharma reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa®
BU
2021Vifor Pharma and American Regent announce settlement of Injectafer® patent litigation
BU
2021Vifor Pharma drives transformation with divestment of non-core finished drug manufactur..
BU
2021Morgan Stanley rates CSL as Equal-weight
AQ
2021CSL Limited announces tender offer to acquire Vifor Pharma Ltd
BU
2021VIFOR PHARMA : comments on media speculation
PU
2021First patient enrolled in phase-IIa study of vamifeport in patients with sickle cell di..
BU
2021Vifor Pharma appoints Hervé Gisserot as new Chief Commercial Officer and member of the ..
BU
2021Vifor Pharma comments on market speculations
BU
2021Vifor Pharma announces changes to the Executive Committee as CFO retires
BU
2021VIFOR PHARMA SUPPORTS IRON DEFICIENC : Call to action for early iron deficiency diagnosis
BU
2021Vifor Pharma to spearhead development of vascular calcification field, through acquisit..
BU
2021ChemoCentryx, Inc. - Positive Recommendation for Use of TAVNEOS (avacopan) in ANCA Vasc..
AQ
2021VFMCRP receives positive CHMP opinion for Tavneos® for the treatment of ANCA-associated..
BU
2021Vifor Pharma and Angion report topline results from phase-III registration trial of ANG..
BU
2021VIFOR PHARMA : announces changes to its Executive Committee
BU
2021CHEMOCENTRYX : Announces FDA Approval of TAVNEOS (avacopan) in ANCA-Associated Vasculitis
AQ
2021VIFOR PHARMA : VFMCRP announces approval for TAVNEOS® (avacopan) for the treatment of ANCA..
BU
2021VIFOR PHARMA : Ferinject® granted new recommendations in updated 2021 ESC heart failure gu..
BU
2021Cara Therapeutics and Vifor Pharma announce U.S. FDA approval of KORSUVA (difelikefalin..
AQ
2021VIFOR PHARMA : and Cara Therapeutics announce U.S. FDA approval of KORSUVA™ injectio..
PU
2021VIFOR PHARMA : reports strong H1 2021 growth, on track to meet full year guidance¹
PU
2021VIFOR PHARMA : Download Half-year Report 2021
PU
2021VIFOR PHARMA : reports strong H1 2021 growth, on track to meet full year guidance1
BU
2021VIFOR PHARMA : Abbas Hussain Appointed as New Chief Executive Officer of Vifor Pharma
BU
2021VIFOR PHARMA : to revise DIAMOND study, readout expected in H2 2021
BU
2021VIFOR PHARMA : 93rd Vifor Pharma Group Annual General Meeting
BU
2021VIFOR PHARMA : VFMCRP announces positive results of phase-III clinical trial of Velphoro® ..
BU
2021VIFOR PHARMA : and Angion announce completion of enrollment in phase-II study of ANG-3777 ..
BU
2021VIFOR PHARMA : First patient enrolled in CARE-HK in HF to evaluate role of Veltassa® (pati..
BU
2021VIFOR PHARMA : to propose Åsa Riisberg for appointment to Board of Directors
BU
2021VIFOR PHARMA : Delivers strong full year results 2020
PU
2021VIFOR PHARMA : Full-year results 2020 – Analyst presentation
PU
2021VIFOR PHARMA : Annual Report 2020 - Full Version
PU
2021VIFOR PHARMA : Annual Report 2020 - Short Version
PU
2021VIFOR PHARMA : delivers strong full year results 2020 with an EBITDA of 576 million Swiss ..
BU
2021VIFOR PHARMA : To propose dr alexandre lebeaut as board member
PU
2021VIFOR PHARMA : to propose Dr Alexandre LeBeaut as Board member
BU
2020ChemoCentryx and VFMCRP Provide Topline Results from ACCOLADE Trial of Avacopan in C3 G..
AQ
2020VIFOR PHARMA : VFMCRP and ChemoCentryx Provide Topline Results From ACCOLADE Trial of Avac..
BU
2020VIFOR PHARMA : supports Iron Deficiency Day 2020 to highlight global impact on health and ..
BU
2020VIFOR PHARMA : VFMCRP and Fresenius Kabi expand collaboration in nephrology in China with ..
BU
2020VIFOR PHARMA : Full results from affirm-ahf study show ferinject significantly reduces hos..
AQ
2020VIFOR PHARMA : Full Results From AFFIRM-AHF Study Show Ferinject® Significantly Reduces Ho..
BU
2020VIFOR PHARMA : and Angion Sign License Agreement for ANG-3777 in Nephrology Indications
BU
2020ChemoCentryx and VFMCRP announce European Medicines Agency has accepted to review the M..
AQ
2020VIFOR PHARMA : VFMCRP and ChemoCentryx announce European Medicines Agency has accepted to ..
BU
2020Vifor Pharma and Cara Therapeutics sign US license agreement for IV Korsuva to treat di..
AQ
2020VIFOR PHARMA : and Cara Therapeutics sign US license agreement for i.v. Korsuva™* to..
BU
2020VIFOR PHARMA : announces outcome of AFFIRM-AHF topline data
AQ
2020VIFOR PHARMA : announces outcome of AFFIRM-AHF topline data
BU
2020VIFOR PHARMA GROUP : Announces Successful Sale of OM Pharma
BU
2020VIFOR PHARMA : Appoints Gregory Oakes as President North America and Member of the Executi..
BU
2020VIFOR PHARMA GROUP : Reports Continued Growth in H1 2020
BU
2020VFMCRP and ChemoCentryx announce topline data from phase-II LUMINA-1 trial of CCX140 in..
AQ
1  2Next
Upcoming event on VIFOR PHARMA AG